CAR-T cell therapy harnesses the immune system to attack blood cancers. Six years after
approving
the first treatment, the FDA is investigating whether it can give rise to secondary cancers.
CAR-T cell therapy harnesses the immune system to attack blood cancers. Six years after
approving the first treatment,
the FDA is investigating whether it can give rise to secondary cancers.
CAR-T cell therapy harnesses the immune system to attack blood cancers. Six years after
approving the first treatment,
the FDA is investigating whether it can give rise to secondary cancers.
CAR-T cell therapy harnesses the immune system to attack blood cancers. Six years after
approving the first treatment,
the FDA is investigating whether it can give rise to secondary cancers.